DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,755 filers reported holding DANAHER CORPORATION in Q1 2021. The put-call ratio across all filers is 0.86 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $11,744,310 | +2.3% | 47,337 | -1.0% | 0.10% | +4.3% |
| Q2 2023 | $11,480,160 | -5.7% | 47,834 | -0.9% | 0.09% | -10.5% |
| Q1 2023 | $12,168,744 | -15.7% | 48,281 | -11.2% | 0.10% | -17.3% |
| Q4 2022 | $14,432,478 | +2.8% | 54,376 | +0.0% | 0.13% | -8.6% |
| Q3 2022 | $14,039,000 | -0.0% | 54,352 | -1.9% | 0.14% | +4.5% |
| Q2 2022 | $14,041,000 | -12.8% | 55,387 | +0.9% | 0.13% | 0.0% |
| Q1 2022 | $16,097,000 | -23.8% | 54,876 | -14.5% | 0.13% | -21.8% |
| Q4 2021 | $21,117,000 | +5.6% | 64,182 | -2.3% | 0.17% | -4.0% |
| Q3 2021 | $20,004,000 | +14.5% | 65,706 | +0.9% | 0.18% | +14.2% |
| Q2 2021 | $17,475,000 | +17.3% | 65,116 | -1.6% | 0.16% | +7.6% |
| Q1 2021 | $14,896,000 | -2.4% | 66,181 | -3.7% | 0.14% | -11.7% |
| Q4 2020 | $15,268,000 | -2.5% | 68,734 | -5.5% | 0.16% | -16.4% |
| Q3 2020 | $15,657,000 | -10.5% | 72,714 | -26.5% | 0.20% | -17.4% |
| Q2 2020 | $17,487,000 | -40.6% | 98,892 | -53.5% | 0.24% | -49.7% |
| Q1 2020 | $29,418,000 | -24.5% | 212,543 | -16.2% | 0.47% | +3.5% |
| Q4 2019 | $38,941,000 | +6.2% | 253,723 | -0.1% | 0.45% | -1.7% |
| Q3 2019 | $36,664,000 | -1.8% | 253,856 | -2.8% | 0.46% | -5.1% |
| Q2 2019 | $37,340,000 | +9.3% | 261,261 | +0.9% | 0.49% | +4.5% |
| Q1 2019 | $34,168,000 | +33.0% | 258,809 | +3.9% | 0.46% | +13.7% |
| Q4 2018 | $25,692,000 | -5.0% | 249,143 | +0.1% | 0.41% | +9.7% |
| Q3 2018 | $27,058,000 | +10.4% | 249,013 | +0.3% | 0.37% | +3.9% |
| Q2 2018 | $24,499,000 | -2.4% | 248,267 | -3.2% | 0.36% | -5.8% |
| Q1 2018 | $25,102,000 | +7.4% | 256,369 | +1.8% | 0.38% | +11.1% |
| Q4 2017 | $23,373,000 | +15.9% | 251,812 | +7.1% | 0.34% | +9.2% |
| Q3 2017 | $20,168,000 | +2818.7% | 235,102 | +2770.6% | 0.31% | +2754.5% |
| Q2 2017 | $691,000 | +29.2% | 8,190 | +30.8% | 0.01% | +37.5% |
| Q1 2017 | $535,000 | -46.3% | 6,260 | -51.1% | 0.01% | 0.0% |
| Q4 2016 | $996,000 | +54.2% | 12,808 | +55.3% | 0.01% | -27.3% |
| Q3 2016 | $646,000 | -22.9% | 8,245 | -0.6% | 0.01% | -21.4% |
| Q2 2016 | $838,000 | +14.0% | 8,295 | +7.1% | 0.01% | +7.7% |
| Q1 2016 | $735,000 | -5.2% | 7,745 | -7.2% | 0.01% | -7.1% |
| Q4 2015 | $775,000 | +25.2% | 8,345 | +14.8% | 0.01% | +40.0% |
| Q3 2015 | $619,000 | -3.0% | 7,270 | -2.5% | 0.01% | 0.0% |
| Q2 2015 | $638,000 | +15.6% | 7,455 | +14.6% | 0.01% | +25.0% |
| Q1 2015 | $552,000 | – | 6,505 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |